Lyra Therapeutics (NASDAQ:LYRA – Get Free Report) and Anika Therapeutics (NASDAQ:ANIK – Get Free Report) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their profitability, institutional ownership, valuation, risk, analyst recommendations, earnings and dividends.
Risk & Volatility
Lyra Therapeutics has a beta of -0.13, meaning that its share price is 113% less volatile than the S&P 500. Comparatively, Anika Therapeutics has a beta of 0.89, meaning that its share price is 11% less volatile than the S&P 500.
Insider & Institutional Ownership
95.6% of Lyra Therapeutics shares are held by institutional investors. Comparatively, 91.5% of Anika Therapeutics shares are held by institutional investors. 4.7% of Lyra Therapeutics shares are held by company insiders. Comparatively, 7.9% of Anika Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Valuation and Earnings
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Lyra Therapeutics | $1.47 million | 9.52 | -$62.68 million | ($1.49) | -0.14 |
| Anika Therapeutics | $164.17 million | 1.56 | -$82.67 million | ($6.65) | -2.62 |
Lyra Therapeutics has higher earnings, but lower revenue than Anika Therapeutics. Anika Therapeutics is trading at a lower price-to-earnings ratio than Lyra Therapeutics, indicating that it is currently the more affordable of the two stocks.
Analyst Recommendations
This is a breakdown of recent recommendations for Lyra Therapeutics and Anika Therapeutics, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Lyra Therapeutics | 1 | 4 | 1 | 0 | 2.00 |
| Anika Therapeutics | 0 | 1 | 1 | 0 | 2.50 |
Lyra Therapeutics presently has a consensus target price of $4.50, suggesting a potential upside of 2,002.80%. Anika Therapeutics has a consensus target price of $24.50, suggesting a potential upside of 40.40%. Given Lyra Therapeutics’ higher possible upside, equities research analysts plainly believe Lyra Therapeutics is more favorable than Anika Therapeutics.
Profitability
This table compares Lyra Therapeutics and Anika Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Lyra Therapeutics | -6,635.76% | -125.07% | -59.74% |
| Anika Therapeutics | -59.40% | -2.22% | -1.75% |
Summary
Anika Therapeutics beats Lyra Therapeutics on 7 of the 13 factors compared between the two stocks.
About Lyra Therapeutics
Lyra Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose, and throat diseases. It's XTreo technology platform is designed to deliver medicines directly to the affected tissue for sustained periods with a single administration. The company's product candidates include LYR-210, an anti-inflammatory implantable drug matrix for the treatment of chronic rhinosinusitis (CRS), which is in Phase III clinical trial; and LYR-220 for CRS patients with and without nasal polyps. It has a collaboration agreement with LianBio Inflammatory Limited to develop and commercialize LYR-210 in mainland China, Hong Kong, Taiwan, Macau, South Korea, Singapore, and Thailand. The company was formerly known as 480 Biomedical, Inc. and changed its name to Lyra Therapeutics, Inc. in July 2018. Lyra Therapeutics, Inc. was incorporated in 2005 and is headquartered in Watertown, Massachusetts.
About Anika Therapeutics
Anika Therapeutics, Inc., a joint preservation company, creates and delivers advancements in early intervention orthopedic care in the areas of osteoarthritis (OA) pain management, regenerative solutions, sports medicine, and arthrosurface joint solutions in the United States, Europe, and internationally. The company develops, manufactures, and commercializes products based on hyaluronic acid (HA) technology platform. Its OA pain management products includes Monovisc and Orthovisc, an injectable HA-based viscosupplement for the pain relief from osteoarthritis conditions; and Cingal, a single-injection OA pain management product to provide both short- and long-term pain relief. The company’s joint preservation and restoration product family comprises and orthopedic regenerative solutions, including Hyalofast and Tactoset; sports medicine solutions used to repair and reconstruct damaged ligaments and tendons; and preserving joint solutions, including partial joint replacement, joint resurfacing, and invasive and bone sparing implants, which are designed to treat upper and lower extremity orthopedic conditions. In addition, it offers non-orthopedic products comprising HA-based products for non-orthopedic applications including Hyvisc, a molecular weight injectable HA veterinary product; Hyalobarrier, an anti-adhesion barrier indicated for use after abdominal-pelvic surgeries; and Hyalomatrix used for the treatment of burns and ulcers, as well as products used for the treatment of ears, nose and throat disorders, and ophthalmic products. The company was founded in 1983 and is headquartered in Bedford, Massachusetts.
Receive News & Ratings for Lyra Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lyra Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
